MX2021005113A - Composiciones de aminoácidos y métodos para el tratamiento de la fibrosis quística. - Google Patents

Composiciones de aminoácidos y métodos para el tratamiento de la fibrosis quística.

Info

Publication number
MX2021005113A
MX2021005113A MX2021005113A MX2021005113A MX2021005113A MX 2021005113 A MX2021005113 A MX 2021005113A MX 2021005113 A MX2021005113 A MX 2021005113A MX 2021005113 A MX2021005113 A MX 2021005113A MX 2021005113 A MX2021005113 A MX 2021005113A
Authority
MX
Mexico
Prior art keywords
cystic fibrosis
methods
amino acid
increasing
acid compositions
Prior art date
Application number
MX2021005113A
Other languages
English (en)
Spanish (es)
Inventor
Sadasivan Vidyasagar
Astrid Grosche
Xiaodong Xu
Shanshan Lin
Sreekala Prabhakaran
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of MX2021005113A publication Critical patent/MX2021005113A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MX2021005113A 2018-10-30 2019-10-30 Composiciones de aminoácidos y métodos para el tratamiento de la fibrosis quística. MX2021005113A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862752847P 2018-10-30 2018-10-30
PCT/US2019/058954 WO2020092639A1 (en) 2018-10-30 2019-10-30 Amino acid compositions and methods for treating cystic fibrosis

Publications (1)

Publication Number Publication Date
MX2021005113A true MX2021005113A (es) 2021-06-15

Family

ID=70464502

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005113A MX2021005113A (es) 2018-10-30 2019-10-30 Composiciones de aminoácidos y métodos para el tratamiento de la fibrosis quística.

Country Status (10)

Country Link
US (1) US12220400B2 (cg-RX-API-DMAC7.html)
EP (1) EP3873453A4 (cg-RX-API-DMAC7.html)
JP (2) JP7689492B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210086660A (cg-RX-API-DMAC7.html)
CN (1) CN113164425B (cg-RX-API-DMAC7.html)
AU (2) AU2019370363B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021008395A2 (cg-RX-API-DMAC7.html)
CA (1) CA3116015A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021005113A (cg-RX-API-DMAC7.html)
WO (1) WO2020092639A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115697301A (zh) * 2020-05-29 2023-02-03 佛罗里达大学研究基金会公司 用于治疗急性呼吸窘迫综合征、哮喘或变应性鼻炎的制剂和方法
US11878073B1 (en) 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224071A1 (en) * 1999-08-20 2003-12-04 Howard Murad Pharmaceutical compositions and methods for managing connective tissue ailments
WO2002028348A2 (en) * 2000-10-04 2002-04-11 The Children's Hospital Of Philadelphia Compositions and methods for treatment of cystic fibrosis
WO2002098405A1 (fr) * 2001-06-05 2002-12-12 Ajinomoto Co., Inc. Inhibiteurs de fibrose du foie
ITTO20010804A1 (it) 2001-08-08 2003-02-08 Professional Dietetics Srl Composizioni a base di aminoacidi, idonee alla terapia per la cicatrizzazione e/o riparazione di ferite e lesioni, in particolare per l'appl
EP1466602A4 (en) * 2001-12-25 2006-03-01 Ajinomoto Kk ORGAN FIBROSIS INHIBITORS
NZ536796A (en) * 2002-04-25 2007-03-30 Scripps Research Inst Treatment and prevention of pulmonary conditions comprising at least one lung surfactant polypeptide and at least one protease inhibitor, lipase inhibitor or an anti-oxidant
EP1513870A4 (en) * 2002-05-31 2006-06-07 Childrens Hosp Medical Center CFTR MODIFIER GENES AND EXPRESSED POLYPEPTIDES SUITABLE FOR THE TREATMENT OF CYSTIC FIBROSIS AND METHOD AND PRODUCTS FOR DETECTING AND / OR IDENTIFYING THEM
AU2003901316A0 (en) * 2003-03-21 2003-04-03 The Royal Alexandra Hospital For Children Regulation of cell surface proteins
US20040253319A1 (en) 2003-06-11 2004-12-16 Shrirang Netke Pharmaceutical compositions and method for alleviating side-effects of estrogen replacement therapy
WO2009051909A1 (en) 2007-10-16 2009-04-23 The Regents Of The University Of California Compounds having activity in correcting mutant-cftr cellular processing and uses thereof
ITTO20080443A1 (it) * 2008-06-06 2009-12-07 Professional Dietetics Srl Composizioni comprendenti amminoacidi, con attivita' pro-angiogenica
PT2664326T (pt) * 2012-05-17 2018-01-19 I E R F C European Institute For Cystic Fibrosis Res Terapia combinada para a fibrose quística
US20140221424A1 (en) 2013-01-30 2014-08-07 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for use in the treatment of cystic fibrosis
MA41031A (fr) * 2014-11-26 2017-10-03 Catabasis Pharmaceuticals Inc Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
WO2016191263A1 (en) 2015-05-22 2016-12-01 Trustees Of Dartmouth College Therapy and kit for the prevention and treatment of cystic fibrosis
CN108463223A (zh) * 2015-10-09 2018-08-28 艾伯维公司 用于治疗囊性纤维化的增效剂-校正剂组合
ES2954658T3 (es) * 2016-06-21 2023-11-23 Proteostasis Therapeutics Inc Compuestos, composiciones y procedimientos para aumentar la actividad de CFTR

Also Published As

Publication number Publication date
CN113164425B (zh) 2026-07-31
JP7689492B2 (ja) 2025-06-06
BR112021008395A2 (pt) 2021-09-28
EP3873453A4 (en) 2022-08-03
US20210393584A1 (en) 2021-12-23
KR20210086660A (ko) 2021-07-08
US12220400B2 (en) 2025-02-11
AU2019370363B2 (en) 2025-07-10
CA3116015A1 (en) 2020-05-07
CN113164425A (zh) 2021-07-23
WO2020092639A1 (en) 2020-05-07
AU2025248660A1 (en) 2025-10-30
AU2019370363A1 (en) 2021-05-13
JP2022506044A (ja) 2022-01-17
JP2025128185A (ja) 2025-09-02
EP3873453A1 (en) 2021-09-08

Similar Documents

Publication Publication Date Title
LT3752510T (lt) Makrocikliniai junginiai kaip cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatoriai, jų farmacinės kompozicijos, jų panaudojimas cistinės fibrozės gydymui ir jų gamybos būdas
JOP20230022A1 (ar) معدلات منظم التوصيل عبر الأغشية للتليف الكيسي
EP4684836A3 (en) Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
MX2021000343A (es) Vesículas para la administración sin trazas de moléculas de arn guía y/o complejos de nucleasa guiado por arn/molécula de arn guía y un método de producción de las mismas.
JOP20230067A1 (ar) معدلات منظم التوصيل عبر الأغشية للتليف الكيسي
MX2022001827A (es) Moduladores del regulador de conductancia transmembrana de la fibrosis quistica.
AU2017260706A1 (en) Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
CL2011000919A1 (es) Compuestos derivados de n-fenil-4-oxo-(1,4-dihidroquinolin o 1h-quinolin)-3-carboxamida, moduladores del regulador de conductancia transmembrana de fibrosis quistica (cftr); compuestos intermediarios; composicion farmaceutica; kit farmaceutico; proceso de preparacion; y uso para el tratamiento de fibrosis quistica, diabetes, entre otros.
WO2014081821A3 (en) Small Molecule Bicyclic and Tricyclic CFTR Correctors
EP4374851A3 (en) Ophthalmic composition for treatment of dry eye disease
SG10201913575VA (en) Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
JOP20240037A1 (ar) مركبات الإندول وطرق الاستخدام
MX2025008949A (es) Arni variante
WO2005120497A3 (en) Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
MX2010005919A (es) Formulaciones de proteinas y metodos para elaborarlas.
EP4364801A3 (en) Optimised dosage of diaminophenothiazines in populations
HK1243340A1 (zh) 透细胞质膜的传递
MX2022007943A (es) Formas farmaceuticas solidas que contienen bacterias y vesiculas extracelulares microbianas.
MX2019012347A (es) Optimizacion de terapia de reemplazo enzimatico para el tratamiento de la homocistinuria.
EA201391006A1 (ru) Гипотоническая водная композиция с пониженным содержанием хлора и с или без фосфолипидов
EA202190481A1 (ru) Трипептиды и лечение метаболических, сердечно-сосудистых и воспалительных заболеваний
MX337114B (es) Soluciones que comprenden polietilenglicol y electrolitos.
MX2018004361A (es) Nuevos compuestos para el tratamiento de la fibrosis quistica.
WO2013134129A3 (en) Derivatized polyglucosamines for delivery of small molecules, peptides, and proteins
IN2012DN00719A (cg-RX-API-DMAC7.html)